Skip to main content

Pemitinib 13.5 mg ( Pemigatinib)

Introduction

Pemitinib 13.5 mg is identified on this website as a product containing pemigatinib, an oral targeted anticancer medicine. Pemigatinib belongs to a group of medicines known as fibroblast growth factor receptor (FGFR) inhibitors.

It works by blocking the activity of three specific receptor proteins: FGFR1, FGFR2 and FGFR3. These proteins are involved in cellular signaling pathways that regulate growth, development, survival and other important biological processes.

In certain cancers, genetic abnormalities can cause FGFR signaling to become excessively active. This abnormal activity may help cancer cells grow and survive. Pemigatinib targets these signaling proteins and interferes with the abnormal signals.

This targeted mechanism is particularly relevant to selected patients with FGFR2-altered cholangiocarcinoma and, under U.S. prescribing information, FGFR1-rearranged myeloid/lymphoid neoplasms.

Understanding Fibroblast Growth Factor Receptors

Fibroblast growth factor receptors are proteins found on the surface of many cells. They belong to a family of receptor tyrosine kinases.

These receptors receive signals from substances called fibroblast growth factors. When a growth factor binds to its receptor, it can activate a series of processes inside the cell.

FGFR signaling contributes to:

  • Normal cell growth and division.
  • Cell differentiation.
  • Tissue development.
  • Cell survival.
  • Blood-vessel formation.
  • Communication between cells.

These functions are important for normal biological activity. However, when genetic abnormalities alter FGFR proteins, the signaling system can become abnormal.

How Abnormal FGFR Signaling Contributes to Cancer

Certain cancer cells develop genetic alterations involving FGFR genes.

These changes may include gene fusions or rearrangements that produce abnormal signaling activity.

As a result, cancer cells may receive persistent signals that encourage growth and survival.

The abnormal pathway can become an important factor in the biology of the tumor. This creates an opportunity for targeted medicines that specifically interfere with FGFR activity.

Not every cancer contains these genetic abnormalities. This is why molecular testing is essential when considering pemigatinib treatment.

Pemigatinib’s Mechanism of Action

Pemigatinib is a small-molecule inhibitor that blocks the kinase activity of FGFR1, FGFR2 and FGFR3.

The kinase domain is the part of a receptor responsible for transferring chemical signals inside the cell.

By inhibiting this activity, pemigatinib reduces signaling through the targeted receptors.

This can interfere with cellular processes that contribute to the growth and survival of cancer cells containing relevant FGFR abnormalities.

Pemigatinib therefore provides a targeted treatment approach based on the molecular characteristics of a patient’s disease.

Why FGFR2 Matters in Cholangiocarcinoma

Cholangiocarcinoma is a cancer that develops in the bile ducts.

Some patients with this disease have tumors containing FGFR2 fusions or qualifying rearrangements.

These genetic changes can contribute to abnormal signaling through the FGFR pathway.

Pemigatinib is used under applicable regulatory labeling in selected adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma containing an eligible FGFR2 alteration.

The medicine is not suitable for every patient with cholangiocarcinoma. Molecular testing must confirm the relevant abnormality, and the patient must meet the other treatment requirements.

Why FGFR1 Matters in Myeloid/Lymphoid Neoplasms

FGFR1 rearrangements are associated with a group of uncommon blood-related cancers known as myeloid/lymphoid neoplasms.

These diseases involve abnormal blood-forming cells and may affect different blood-cell lineages.

An FGFR1 rearrangement can result in abnormal signaling that contributes to disease development and progression.

Pemigatinib inhibits FGFR1 activity and is included in U.S. prescribing information for adults with relapsed or refractory myeloid/lymphoid neoplasms containing an FGFR1 rearrangement.

This indication has different eligibility requirements and a different treatment schedule from the cholangiocarcinoma indication.

Why Molecular Testing Is Important

Molecular testing helps identify the genetic characteristics of a cancer.

For patients being considered for pemigatinib treatment, testing may establish whether the tumor contains a relevant FGFR2 fusion or rearrangement or whether an FGFR1 rearrangement is present in the applicable blood-related disease.

Testing is important because pemigatinib’s targeted action depends on the relevant molecular abnormality.

A general diagnosis of cancer does not establish eligibility.

The treating specialist must review the molecular findings and determine whether the results meet the applicable regulatory and clinical requirements.

How Targeted Treatment Differs From Conventional Chemotherapy

Conventional chemotherapy medicines generally act on rapidly dividing cells through mechanisms that may affect both cancerous and healthy tissues.

Targeted therapies work differently. They are designed to interfere with particular molecules or signaling pathways involved in cancer development.

Pemigatinib is an example of targeted treatment because it inhibits selected FGFR proteins.

However, targeted therapy does not mean that a medicine has no side effects. Pemigatinib can produce significant adverse reactions and requires appropriate medical supervision.

How Pemigatinib Affects Phosphate Regulation

FGFR signaling is involved in normal phosphate regulation.

When pemigatinib inhibits FGFR activity, the body’s phosphate balance may change. This can result in hyperphosphatemia, an increase in phosphate concentration in the blood.

High phosphate levels may contribute to calcium-phosphate deposition in soft tissues.

Healthcare professionals monitor blood phosphate levels during treatment. Depending on the results, management may include dietary changes, phosphate-lowering medicines, dose interruption or dose modification.

Why Eye Monitoring Is Necessary

Pemigatinib may cause ocular adverse reactions, including retinal pigment epithelial detachment.

This condition affects the retina and may interfere with normal vision.

Patients should undergo recommended eye examinations, including optical coherence tomography, before and during treatment.

New blurred vision, flashes of light, visual floaters or other changes in eyesight should be reported promptly.

Does Pemigatinib Work for Every Patient?

No. Treatment response varies between individuals.

The presence of a qualifying molecular abnormality is an important eligibility consideration, but it does not guarantee that a patient will respond to treatment.

Treatment decisions also depend on disease status, previous therapies, overall health, organ function and the ability to tolerate potential adverse reactions.

The treating specialist evaluates these factors when deciding whether pemigatinib is appropriate.

Conclusion

Pemigatinib works by inhibiting FGFR1, FGFR2 and FGFR3, interfering with abnormal signaling pathways that can contribute to cancer growth and survival.

Its targeted mechanism supports its use in selected molecularly defined cancer populations.

Molecular testing, professional prescribing and regular safety monitoring are essential parts of treatment.